Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers

Exclusion Criteria

• •1. Current pregnancy or lactation.
• •2. Presence of severe facial acne, acne fulminans or conglobata, or nodulocystic acne.
• •3. Poor skin condition on the back, including erythema, dryness, sunburn, dermatological malignancies, infections, cuts, abrasions, tattoo, excess of hair or any other skin condition
• •4. Subjects who have used any agents known to produce significant photosensitivity reactions (tetracyclines, phenothiazines, trimethoprim, etc.) within 2 weeks of Day 1 or 5 half-lives, whichever is longer.
• •5. Subjects who have used any medicated topical therapy on the back within 3 days of Day 1.
• •6. Chronic treatment with low dose aspirin, a non-steroidal anti inflammatory drug (NSAID), or an anticoagulant regimen such as warfarin (Coumadin).
• •7. Abnormal findings on screening ECG deemed clinically significant by the Investigator.
• •8. Active participation in an experimental therapy study or experimental therapy within 30 days of Day 1.
• •9. Screening clinical chemistry or hematology laboratory value that is considered clinically significant, in the opinion of the Investigator.
• •10. Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections.